



## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Drug Abuse; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute on Drug Abuse Special Emphasis Panel Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose

**Date:** August 2, 2023

**Time:** 12:30 PM to 1:00 PM

**Agenda:** To review and evaluate grant applications

**Place:** National Institute of Health  
National Institute on Drug Abuse  
301 North Stonestreet Avenue  
Bethesda, MD 20892  
(Virtual Meeting)

**Contact Person:** Sudhirkumar Udhavrao Yanpallewar, M.D.  
Scientific Review Officer  
Scientific Review Branch  
National Institute on Drug Abuse, NIH  
301 North Stonestreet Avenue  
Bethesda, MD 20892  
(301) 443-4577  
[sudhirkumar.yanpallewar@nih.gov](mailto:sudhirkumar.yanpallewar@nih.gov)

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist

Development Award for Clinicians, Scientist Development Awards, and Research Scientist

Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279,  
Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: June 26, 2023.

**Miguelina Perez,**

*Program Analyst,*

*Office of Federal Advisory Committee Policy.*

[FR Doc. 2023-13906 Filed: 6/29/2023 8:45 am; Publication Date: 6/30/2023]